HIGHLIGHTS
SUMMARY
Calabro et_al, 2019 Singleblinded, parallel group Eligibility Criteria Inclusion: Diagnosed with PD (H and amp;Y 2-3), showed no cognitive impairments (MMSE > 23), on a stable antiparkinsonian treatment regimen over previous 6 months. Song et_al, 2015 Singleblinded, prospectiv e group Inclusion: Valid clinical diagnosis of PD, no cognitive impairment, able to walk independently following intake of conventional anti-PD drugs Exclusion: Other disorders affecting the nervous system, vision and hearing impairments. Braun Janzen et_al, 2019 Singleblinded, parallel group (Mixeddesign ANOVA) Inclusion: Diagnosed with PD (H and amp;Y 1-2), on a stable . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.